Zynteglo halt re-ignites viral vector safety concerns; analysts
pharmaphorum
FEBRUARY 22, 2021
One UK company that could be affected greatly by that is Oxford BioMedica , which has built a business around its LentiVector delivery platform used in Kymriah and other emerging therapies, according to Jefferies. million in Europe. The post Zynteglo halt re-ignites viral vector safety concerns; analysts appeared first on.
52 
Let's personalize your content